Letter of Offer dated July 18, 2026 received from SBI Capital Markets Limited, the manager to the Open Offer appointed by Anupam Rasayan India Limited along with PAC.

July 21, 2026 To To The Manager, Listing Department The General Manager, Listing Department National Stock Exchange of India Ltd. BSE Limited Plot no. C/1 G Block, Phiroze Jeejeebhoy Towers, Bandra-Kurla Complex, Bandra (East), Dalal Street, Mumbai- 400 051 Mumbai- 400 001 Symbol: BLISSGVS Scrip Code: 506197 Sub: Letter of Offer dated July 18, 2026 received from SBI Capital Markets Limited. Dear Sir / Madam, With reference to the captioned subject, we hereby inform you that, the Company has received Letter of Offer dated July 18, 2026 (“LOF”) from SBI Capital Markets Limited (SEBI Registration No. INM000003531), the Manager to the Open Offer appointed by Anupam Rasayan India Limited (“Acquirer”) along with PAC. A copy of the aforesaid LOF as received by the Company, is enclosed herewith for your information and records. Kindly take the above information on record. Thanking you, Yours Faithfully, For Bliss GVS Pharma Limited Aditi H. Bhatt Company Secretary Encl: As above July 21, 2026 Bliss GVS Pharma Limited 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai, Maharashtra - 400072. Dear Sir/Madam, Subject: Open offer for acquisition of up to 2,77,26,848 (Two Crore Seventy-Seven Lakh Twenty-Six Thousand Eight Hundred Forty-Eight) fully paid-up equity shares of face value of ₹ 1 (Indian Rupee One) each (the “Equity Shares”), of Bliss GVS Pharma Limited (“Target Company”), representing 26.00% (Twenty-Six per cent) of the Expanded Voting Share Capital from the eligible public shareholders of the Target Company by Anupam Rasayan India Limited (“Acquirer”) along with Mates Visa Consultancy Private Limited (“PAC”) in its capacity as person acting in concert with the Acquirer pursuant to and in compliance with the requirements of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 as amended (the “SEBI (SAST) Regulations”) (the “Open Offer”/“Offer”). With respect to the captioned Offer, please refer enclosed copy of the Letter of Offer dated July 18, 2026 (“LOF”). A copy of the LOF has also been shared with the stock exchanges on which the Equity Shares of the Target Company are listed, which are BSE Limited (Scrip ID – 506197), National Stock Exchange of India Limited (Scrip ID – BLISSGVS). Capitalized terms used in this letter unless defined herein shall have the same meanings as ascribed to them in the attached LOF. Thanking You, SBI Capital Markets Limited Authorized Signatory Name: Sylvia Mendonca Designation: Vice President Enclosed- As stated above Registered Office: SBI Capital Markets Limited, 1501, 15th floor, A & B Wing, Parinee Crescenzo Building, G Block, Bandra Kurla Complex, Bandra East, Mumbai- 400 051 | Tel: 4196 8300 | Email: corporate.office@sbicaps.com Web: www.sbicaps.com | CIN: U99999MH1986PL040298 A Subsidiary of State Bank of India LETTER OF OFFER THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION This Letter of Offer (as defined below) is being sent to you as a Public Shareholder (as defined below) of Bliss GVS Pharma Limited. If you require any clarification about the action to be taken, you may consult your stockbroker or investment consultant or the Manager to the Offer (as defined below)/ the Registrar to the Offer (as defined below). In case you have recently sold your Equity Shares (as defined below) in Bliss GVS Pharma Limited, please hand over this Letter of Offer and the accompanying Form of Acceptance-cum-Acknowledgement (as defined below) to the member of Stock Exchange (as defined below) through whom the said sale was effected. OPEN OFFER (“OPEN OFFER”/ “OFFER”) ANUPAM RASAYAN INDIA LIMITED A public limited company incorporated under the laws of India Regd. Office: Office Nos.1101 to1107, 11th Floor, Icon Rio, Behind Icon Business Centre, Dumas Road, Piplod, Surat, Gujarat - 395007 Corporate Identity Number (CIN): L24231GJ2003PLC042988 (Tel: 261-2398991-95; Fax: 261-2398996) (hereinafter referred to as the “Acquirer”) ALONGWITH MATES VISA CONSULTANCY PRIVATE LIMITED A private company incorporated under the laws of India Regd. Office: GN3-209, N.P.C. (New Prem Colony), Karnal, Karnal, Haryana, India, 132001 Corporate Identity Number (CIN): U74999HR2022PTC103913 (Tel: +91 9016564657) (hereinafter referred to as “PAC”) MAKES A CASH OFFER TO ACQUIRE UP TO 2,77,26,848 (TWO CRORE SEVENTY-SEVEN LAKH TWENTY-SIX THOUSAND EIGHT HUNDRED FORTY-EIGHT) FULLY PAID-UP EQUITY SHARES OF FACE VALUE OF ₹1 (INDIAN RUPEE ONE) EACH (“OFFER SHARES”) AT A PRICE OF ₹ 299.00 (INDIAN RUPEES TWO HUNDRED NINETY-NINE ONLY) PER EQUITY SHARE (“OFFER PRICE”), REPRESENTING 26.00% (TWENTY-SIX PER CENT.) OF THE EXPANDED VOTING SHARE CAPITAL (AS DEFINED BELOW) OF THE TARGET COMPANY (AS DEFINED BELOW), IN ACCORDANCE WITH THE SECURITIES AND EXCHANGE BOARD OF INDIA (SUBSTANTIAL ACQUISITION OF SHARES AND TAKEOVERS) REGULATIONS, 2011 AND SUBSEQUENT AMENDMENTS THERETO (SEBI (SAST) REGULATIONS) FROM THE PUBLIC SHAREHOLDERS (AS DEFINED BELOW). BLISS GVS PHARMA LIMITED Regd. office: 102, Hyde Park, Sakivihar Road, Andheri (East), Mumbai, Maharashtra - 400072 Corporate identification Number: L24230MH1984PLC034771 (Tel: 022-42160000; Fax: 022-28563930 Email Address: Project.compliance@blissgvs.com; Website:www.blissgvs.com (hereinafter referred to as “Target Company”) 1. This Open Offer is being made by the Acquirer and the PAC, pursuant to and in compliance with the provisions of Regulation 3(1), Regulation 4 and other applicable regulations of the SEBI (SAST) Regulations. 2. This Open Offer is not a conditional offer in terms of Regulation 19 of the SEBI (SAST) Regulations and is not subject to any minimum level of acceptance. 3. This Open Offer is not a competing offer in terms of Regulation 20 of the SEBI (SAST) Regulations. 4. NRI (as defined below) and OCB (as defined below) holders of Equity Shares, if any, willing to tender their Equity Shares in this Open Offer, must obtain all requisite approvals required to tender the Equity Shares held by them in this Offer (including, without limitation, approval from the RBI (as defined below), or any other relevant statutory or regulatory authority, as may be applicable and submit copies of such approvals, along with the Form of Acceptance-cum-Acknowledgement and other documents required in terms of this Letter of Offer. Further, if holders of the Equity Shares who are not persons resident in India (including NRIs, OCBs, and FPIs (as defined below)), willing to tender their Equity Shares in this Open Offer, had required any approvals (including from the RBI or any other regulatory/statutory authority) in respect of the Equity Shares held by them at the time of original investment, they will be required to submit copies of such previous approvals, along with the other documents required to be tendered to accept this Open Offer. In the event such approvals are not submitted, the Acquirer and the PAC reserve the right to reject such Equity Shares tendered in this Open Offer. If the Equity Shares are held under general permission of the RBI, the non-resident Public Shareholder should state that the Equity Shares are held under general permission and clarify whether the Equity Shares are held on a repatriable or a non-repatriable basis. 5. There are no statutory or regulatory approvals required by the Acquirer and/ or the PAC, to acquire the Equity Shares validly tendered by Public Shareholders pursuant to this Open Offer. However, in case of any other statutory or regulatory approvals being required and/or becoming applicable at a later date, before the closing of the Tendering Period (as defined below), this Open Offer would be subject to the receipt of such approvals. Please refer to Part C (Statutory and Other Approvals) of Section VIII (Terms and Conditions of the Open Offer) of this Letter of Offer for further details and the current status of such statutory and governmental approval(s). 6. Where any statutory or other approval extends to so [Showing first 8,000 characters — download PDF for full document]